Background Background It remains unclear how
It remains unclear how much various factors contribute to the much various factors contribute to the placebo response. placebo response.
Aims
Aims To estimate the therapeutic To estimate the therapeutic impact of follow-up assessments on impact of follow-up assessments on placebo response in antidepressanttrials. placebo response in antidepressanttrials.
Method
Method Double-blind, placebo-Double-blind, placebocontrolled antidepressanttrials that controlled antidepressanttrials that reported weekly changes in Hamilton reported weekly changes in Hamilton Rating Scale for Depression (HRSD) Rating Scale for Depression (HRSD) scores over 6 weeks were selected. scores over 6 weeks were selected. Included studies ( Included studies (n n¼41) were divided into 41) were divided into those that conducted four, five or six those that conducted four, five or six follow-up assessments.Reductions in follow-up assessments.Reductions in HRSD scores as a function of the different HRSD scores as a function of the different follow-up schedules were compared. follow-up schedules were compared.
Results

Results An extra follow-up visit at
An extra follow-up visit at week 3 was associated with a 0.86 further week 3 was associated with a 0.86 further reduction in HRSD score; an extra visit at reduction in HRSD score; an extra visit at week 5 was associated with a 0.67 further week 5 was associated with a 0.67 further reduction.These effects represented reduction.These effects represented approximately 34^44% of the placebo approximately 34^44% of the placebo response that occurred over these time response that occurred over these time frames.Two additional visits were frames.Two additional visits were associated with twice the reduction in associated with twice the reduction in HRSD score than one, suggesting thatthe HRSD score than one, suggesting thatthe therapeutic impact of assessment visits is therapeutic impact of assessment visits is cumulative and proportional. A com-cumulative and proportional. A comparable therapeutic effect was also found parable therapeutic effect was also found in participants receiving active medication. in participantsreceivingactive medication.
Conclusions Conclusions Follow-up assessments in
Follow-up assessments in antidepressanttreatmenttrials incur a antidepressanttreatmenttrials incur a significanttherapeutic effect for significanttherapeutic effect for participants on placebo, and this participants on placebo, and this represents about 40% of the placebo represents about 40% of the placebo response. response.
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Reports in both scientific journals and the Reports in both scientific journals and the media have questioned whether the true media have questioned whether the true benefits of antidepressant medications have benefits of antidepressant medications have been exaggerated (Goleman, 1995; Fisher been exaggerated (Goleman, 1995; Fisher & Greenberg, 1997; Horgan, 1998; Kirsch & Greenberg, 1997; Horgan, 1998; Kirsch & Sapirstein, 1999) , and a recent review of & Sapirstein, 1999) , and a recent review of the Food and Drug Administration (FDA) the Food and Drug Administration (FDA) database found that that as many as half database found that that as many as half of antidepressant trials yield negative re-of antidepressant trials yield negative results (Khan sults (Khan et al et al, 2002) . A major hindrance , 2002). A major hindrance to establishing antidepressant efficacy is the to establishing antidepressant efficacy is the remarkably high rates of improvement remarkably high rates of improvement among participants receiving placebo, among participants receiving placebo, which have been increasing over the past which have been increasing over the past two decades (Walsh two decades (Walsh et al et al, 2002) . Factors , 2002) . Factors that have been implicated in the placebo that have been implicated in the placebo response include the instillation of hope, response include the instillation of hope, response expectancies (Kirsch, 1985) , response expectancies (Kirsch, 1985) , motivation to please investigators (Orne, motivation to please investigators (Orne, 1969) , the therapeutic impact of 1969), the therapeutic impact of assessment contact, rater bias and sponta-assessment contact, rater bias and spontaneous improvement (Harrington, 1999) . A neous improvement (Harrington, 1999) . A better understanding of how much each better understanding of how much each contributes would allow a more accurate contributes would allow a more accurate gauge of the true antidepressant effect and gauge of the true antidepressant effect and could lead to improved trial designs. could lead to improved trial designs.
In the present study, we sought to In the present study, we sought to evaluate the therapeutic impact of frequent evaluate the therapeutic impact of frequent follow-up assessments. In standard anti-follow-up assessments. In standard antidepressant trials, participants are usually depressant trials, participants are usually seen on a weekly basis to assess depression seen on a weekly basis to assess depression severity, level of functioning and side-severity, level of functioning and sideeffects. Such visits typically last 30 min or effects. Such visits typically last 30 min or more and are conducted by trained research more and are conducted by trained research assistants over the course of 6 weeks. The assistants over the course of 6 weeks. The impact of so much contact with a health-impact of so much contact with a healthcare provider is unknown but could be care provider is unknown but could be substantial. Furthermore, this amount of substantial. Furthermore, this amount of contact is much greater than in routine clin-contact is much greater than in routine clinical practice where two to three 15-min ical practice where two to three 15-min visits for management of medication are visits for management of medication are the norm (Posternak the norm (Posternak et al et al, 2002 (Posternak et al et al, , 2002a . To eval-). To evaluate the impact of these follow-up assess-uate the impact of these follow-up assessments, we conducted a meta-analysis of ments, we conducted a meta-analysis of 41 double-blind, placebo-controlled anti-41 double-blind, placebo-controlled antidepressant trials published over the past depressant trials published over the past two decades. We primarily focused on the two decades. We primarily focused on the impact that follow-up assessments had on impact that follow-up assessments had on the placebo response but also examined the placebo response but also examined their effect on participants receiving active their effect on participants receiving active medication. medication.
METHOD METHOD
Sources of data and criteria Sources of data and criteria for review for review
The collection of studies used here is the The collection of studies used here is the same as in our previous meta-analysis same as in our previous meta-analysis which evaluated the time course of which evaluated the time course of improvement on antidepressant medication improvement on antidepressant medication and placebo (Posternak & Zimmerman, and placebo (Posternak & Zimmerman, 2005) . These studies were compiled by 2005). These studies were compiled by reviewing the bibliography of the meta-reviewing the bibliography of the metaanalysis evaluating placebo response rates analysis evaluating placebo response rates in antidepressant trials published over the in antidepressant trials published over the past two decades (Walsh past two decades (Walsh et al et al, 2002) . To major depressive disorder according to Re-major depressive disorder according to Research Diagnostic Criteria (RDC; Spitzer search Diagnostic Criteria (RDC; ; (d) had at least 20 participants in , 1978); (d) had at least 20 participants in the placebo group; (e) randomly assigned the placebo group; (e) randomly assigned participants to receive a putative antide-participants to receive a putative antidepressant drug or drugs and placebo; (f) re-pressant drug or drugs and placebo; (f) reported the total number of participants ported the total number of participants assigned to placebo and medication assigned to placebo and medication group(s); (g) assessed participants under group(s); (g) assessed participants under double-blind conditions; and (h) utilised double-blind conditions; and (h) utilised the Hamilton Rating Scale for Depression the Hamilton Rating Scale for Depression (HRSD; Hamilton, 1960) to assess im-(HRSD; Hamilton, 1960) to assess improvement. We excluded studies that did provement. We excluded studies that did not report mean baseline HRSD scores, not report mean baseline HRSD scores, did not present weekly or biweekly (every did not present weekly or biweekly (every other week) changes in HRSD scores, eval-other week) changes in HRSD scores, evaluated agents with unproven antidepressant uated agents with unproven antidepressant properties or evaluated accepted anti-properties or evaluated accepted antidepressant agents that were used at sub-depressant agents that were used at subtherapeutic doses, or focused on specific therapeutic doses, or focused on specific subpopulations of patients such as the subpopulations of patients such as the elderly. Forty-seven trials that met these elderly. Forty-seven trials that met these inclusion criteria were included in our inclusion criteria were included in our original meta-analysis. Of these, we original meta-analysis. Of these, we excluded six studies (Claghorn excluded six studies (Claghorn et al et al, 1983; , 1983; Dominguez Dominguez et al et al, 1985; Hormazabal , 1985; Hormazabal et al et al, , 1985; Amsterdam 1985; Amsterdam et al et al, 1986; Ferguson , 1986; Ferguson et et al al, 1994; Khan, 1995) for the present , 1994; Khan, 1995) for the present meta-analysis because they did not conduct meta-analysis because they did not conduct outcome assessments at week 6. outcome assessments at week 6.
Follow-up schedules Follow-up schedules
For the 41 studies included in the present For the 41 studies included in the present meta-analysis, three types of follow-up meta-analysis, three types of follow-up schedules were used: 15 studies (Cohn & schedules were used: 15 studies (Cohn & Wilcox, 1985; Byerley Wilcox, 1985; Byerley et al et al, 1988; Cohn , 1988; Cohn et al et al, 1989; Lineberry , 1989; Lineberry et al et al, 1990; Reimherr , 1990; Reimherr et al et al, 1990; Smith , 1990; Smith et al et al, 1990; Fontaine , 1990; Fontaine et et al al, 1994; Heiligenstein , 1994; Heiligenstein et al et al, 1994; Wilcox , 1994; Wilcox et al et al, 1994; Bremner, 1995; Claghorn & , 1994; Bremner, 1995; Claghorn & Lesem, 1995; Fabre Lesem, 1995; Fabre et al et al, 1995; Mendels , 1995; Mendels et al et al, 1995; Claghorn , 1995; Claghorn et al et al, 1996; , 1996; Schatzberg, 2000) conducted weekly Schatzberg, 2000) conducted weekly follow-up assessments over the course of 6 follow-up assessments over the course of 6 weeks (weekly cohort); 19 studies (Feighner weeks (weekly cohort); 19 studies (Feighner & Boyer, 1989; Versiani & Boyer, 1989; Versiani et al et al, 1989; , 1989; Gelenberg Gelenberg et al et al, 1990; Claghorn , 1990; Claghorn et al et al, , 1992; Cohn & Wilcox, 1992; Fabre, 1992; Cohn & Wilcox, 1992; Fabre, 1992; Kiev, 1992; Rickels 1992; Kiev, 1992; Rickels et al et al, 1992; , 1992; Shrivastava Shrivastava et al et al, 1992; Smith & Glaudin, , 1992; Smith & Glaudin, 1992; Mendels 1992; Mendels et al et al, 1993; Cunningham , 1993; Cunningham et al et al, 1994; Cunningham, 1997; Thase, , 1994; Cunningham, 1997; Thase, 1997; Khan 1997; Khan et al et al, 1998; Rudolph , 1998; Rudolph et al et al, , 1998; Rudolph & Feiger, 1999; Silverstone 1998; Rudolph & Feiger, 1999; Silverstone & Ravindran, 1999; Stahl, 2000 ) con-& Ravindran, 1999 Stahl, 2000) conducted assessments at weeks 1, 2, 3, 4 and ducted assessments at weeks 1, 2, 3, 4 and 6 without an assessment at week 5 (skip 6 without an assessment at week 5 (skip week 5 cohort); 7 studies (Feighner week 5 cohort); 7 studies (Feighner et al et al, , 1983; Merideth & Feighner, 1983; Rickels 1983; Merideth & Feighner, 1983; Rickels et al et al, 1985; Mendels & Schless, 1986; , 1985; Mendels & Schless, 1986; Rickels Rickels et al et al, 1991; Anonymous, 1994; , 1991; Anonymous, 1994; Laakman Laakman et al et al, 1995) conducted assess-, 1995) conducted assessments at weeks 1, 2, 4 and 6 without assess-ments at weeks 1, 2, 4 and 6 without assessments at weeks 3 and 5 (skip weeks 3 and 5 ments at weeks 3 and 5 (skip weeks 3 and 5 cohort). We utilised these differences in cohort). We utilised these differences in follow-up schedules as a way to focus on follow-up schedules as a way to focus on the specific therapeutic effects of follow-the specific therapeutic effects of followup assessments. up assessments.
Establishing reduction in HRSD Establishing reduction in HRSD scores scores
The method for establishing mean baseline The method for establishing mean baseline scores and weekly improvement in HRSD scores and weekly improvement in HRSD scores is the same as in our previous scores is the same as in our previous meta-analysis (Posternak & Zimmerman, meta-analysis (Posternak & Zimmerman, 2005) . Baseline HRSD scores and weekly 2005). Baseline HRSD scores and weekly reductions in HRSD scores were established reductions in HRSD scores were established for each study, and all analyses accounted for each study, and all analyses accounted for differences in sample size between for differences in sample size between studies. Some studies depicted changes in studies. Some studies depicted changes in HRSD scores graphically. In these in-HRSD scores graphically. In these instances, weekly changes in HRSD scores stances, weekly changes in HRSD scores were obtained by measuring each data-were obtained by measuring each datapoint with rounding to the nearest 0.5. A point with rounding to the nearest 0.5. A research assistant who was unaware of the research assistant who was unaware of the purposes of the study remeasured each purposes of the study remeasured each data-point. Of the 476 data-points data-point. Of the 476 data-points extracted from graphs, 456 (95.8%) were extracted from graphs, 456 (95.8%) were remeasured by the research assistant within remeasured by the research assistant within 0.5 points, suggesting that data extraction 0.5 points, suggesting that data extraction was performed reliably and without bias. was performed reliably and without bias.
Hypotheses Hypotheses
We hypothesised that follow-up assess-We hypothesised that follow-up assessments would have a discernible therapeutic ments would have a discernible therapeutic effect on placebo response rates. Differ-effect on placebo response rates. Differences in follow-up schedules allowed us to ences in follow-up schedules allowed us to compare reductions in HRSD scores in compare reductions in HRSD scores in cohorts that met on a weekly basis with cohorts that met on a weekly basis with those that by design skipped 1 or 2 weeks. those that by design skipped 1 or 2 weeks. Our specific hypotheses were: (a) reduc-Our specific hypotheses were: (a) reductions in HRSD scores from week 4 to week tions in HRSD scores from week 4 to week 6 will be greater for the weekly cohort com-6 will be greater for the weekly cohort compared with the skip week 5 and skip weeks pared with the skip week 5 and skip weeks 3 and 5 cohort; (b) reductions in HRSD 3 and 5 cohort; (b) reductions in HRSD scores from week 2 to week 4 will be great-scores from week 2 to week 4 will be greater for the weekly cohort and the skip week er for the weekly cohort and the skip week 5 cohort compared with the skip weeks 3 5 cohort compared with the skip weeks 3 and 5 cohort; (c) there will be a propor-and 5 cohort; (c) there will be a proportional and cumulative therapeutic effect of tional and cumulative therapeutic effect of having multiple extra assessments; to exam-having multiple extra assessments; to examine this question, we compared reductions ine this question, we compared reductions in HRSD scores from week 2 to week 6 in in HRSD scores from week 2 to week 6 in the skip weeks 3 and 5 cohort, skip week the skip weeks 3 and 5 cohort, skip week 5 cohort, and the weekly cohort; (d) to 5 cohort, and the weekly cohort; (d) to confirm that placebo effects do not differ confirm that placebo effects do not differ between cohorts, we predicted that reduc-between cohorts, we predicted that reductions in HRSD scores would be comparable tions in HRSD scores would be comparable between cohorts from baseline through between cohorts from baseline through week 2; because we considered this the week 2; because we considered this the most direct method to confirm that there most direct method to confirm that there are no random differences in placebo are no random differences in placebo response rates, we deemed it unnecessary response rates, we deemed it unnecessary to control for potential confounding vari-to control for potential confounding variables such as fixed ables such as fixed v.
v. flexible dose design, flexible dose design, year of publication, etc.; (e) if follow-up as-year of publication, etc.; (e) if follow-up assessments are found to convey a therapeutic sessments are found to convey a therapeutic effect for participants receiving placebo, we effect for participants receiving placebo, we would predict that all of the above findings would predict that all of the above findings would be replicated in cohorts receiving would be replicated in cohorts receiving antidepressant medication. antidepressant medication.
Finally, if follow-up assessments convey a Finally, if follow-up assessments convey a non-specific therapeutic effect, we hypothe-non-specific therapeutic effect, we hypothesised that treatment effect sizes would be sised that treatment effect sizes would be greater in trials with fewer follow-up greater in trials with fewer follow-up assessments. However, only a handful of assessments. However, only a handful of studies published weekly or end-point stand-studies published weekly or end-point standard deviations. Therefore, we were unable to ard deviations. Therefore, we were unable to establish effect sizes or confidence intervals. establish effect sizes or confidence intervals.
RESULTS
Cohorts Cohorts
For participants randomised to placebo, the For participants randomised to placebo, the weekly cohort comprised 941 people from weekly cohort comprised 941 people from 15 separate studies; the skip week 5 cohort 15 separate studies; the skip week 5 cohort comprised 1449 people drawn from 19 comprised 1449 people drawn from 19 studies and the skip weeks 3 and 5 cohort studies and the skip weeks 3 and 5 cohort comprised 673 participants drawn from 7 comprised 673 participants drawn from 7 studies. The baseline mean HRSD scores studies. The baseline mean HRSD scores for these three groups were 25.6 for these three groups were 25.6 (s. 2.53) respectively. For participants randomised to active For participants randomised to active medication, the weekly cohort comprised medication, the weekly cohort comprised 1507 people from 25 cohorts (some studies 1507 people from 25 cohorts (some studies included more than one active medication included more than one active medication group); the skip week 5 cohort comprised group); the skip week 5 cohort comprised 2284 people from 31 cohorts and the skip 2284 people from 31 cohorts and the skip weeks 3 and 5 cohort comprised 820 parti-weeks 3 and 5 cohort comprised 820 participants from 9 cohorts. The baseline HRSD cipants from 9 cohorts. The baseline HRSD scores for these three groups were 25.6 scores for these three groups were 25.6 (s. Week 5 assessment
Week 5 assessment
From week 4 to week 6, the mean decrease From week 4 to week 6, the mean decrease in HRSD scores for cohorts receiving in HRSD scores for cohorts receiving placebo that met at week 5 (the weekly co-placebo that met at week 5 (the weekly cohort) was 1.52 points. For cohorts that did hort) was 1.52 points. For cohorts that did not meet at week 5 (the skip week 5 and the not meet at week 5 (the skip week 5 and the skip weeks 3 and 5 cohorts), the mean de-skip weeks 3 and 5 cohorts), the mean decrease in HRSD scores from week 4 to crease in HRSD scores from week 4 to week 6 was 0.85 points. Thus, participants week 6 was 0.85 points. Thus, participants who returned for an extra follow-up visit at who returned for an extra follow-up visit at week 5 experienced a 0.67 greater reduc-week 5 experienced a 0.67 greater reduction in HRSD scores over this 2-week tion in HRSD scores over this 2-week period than those who did not have a week period than those who did not have a week 5 visit. This difference represents 44% of 5 visit. This difference represents 44% of the decrease in HRSD scores over this the decrease in HRSD scores over this period. period.
Week 3 assessment Week 3 assessment
From week 2 to week 4, the mean decrease From week 2 to week 4, the mean decrease in HRSD scores for cohorts receiving pla-in HRSD scores for cohorts receiving placebo that met at week 3 (the weekly cohort cebo that met at week 3 (the weekly cohort and skip week 5 cohort) was 2.56 points. and skip week 5 cohort) was 2.56 points. For cohorts that did not have a scheduled For cohorts that did not have a scheduled follow-up assessment at week 3 (the skip follow-up assessment at week 3 (the skip weeks 3 and 5 cohort), the mean decrease weeks 3 and 5 cohort), the mean decrease in HRSD scores from week 2 to week 4 in HRSD scores from week 2 to week 4 was 1.70 points. Thus, participants who was 1.70 points. Thus, participants who returned for an extra follow-up visit at returned for an extra follow-up visit at week 3 experienced a 0.86 greater reduc-week 3 experienced a 0.86 greater reduction in HRSD scores over this 2-week tion in HRSD scores over this 2-week period than those who did not have a week period than those who did not have a week 3 follow-up visit. This represents 34% of 3 follow-up visit. This represents 34% of the decrease in HRSD scores over this the decrease in HRSD scores over this period. period.
Therapeutic impact of multiple Therapeutic impact of multiple extra assessments extra assessments
To examine whether there is a cumulative To examine whether there is a cumulative and proportional therapeutic impact of and proportional therapeutic impact of multiple extra assessments, we compared multiple extra assessments, we compared reductions in HRSD scores from week 2 to reductions in HRSD scores from week 2 to week 6 in the weekly cohort with reduc-week 6 in the weekly cohort with reductions in the skip week 5 and skip weeks 3 tions in the skip week 5 and skip weeks 3 and 5 cohorts. The first group had four and 5 cohorts. The first group had four scheduled follow-up assessments, the sec-scheduled follow-up assessments, the second group had three and the third group ond group had three and the third group had two. Reductions in HRSD scores were had two. Reductions in HRSD scores were 4.24, 3.33 and 2.49 points respectively. 4.24, 3.33 and 2.49 points respectively. Thus, the reduction with one extra Thus, the reduction with one extra assessment (skip weeks 3 and 5 cohort assessment (skip weeks 3 and 5 cohort v. v. skip week 5 cohort) was 0.84 HRSD points skip week 5 cohort) was 0.84 HRSD points whereas that with two extra assessments whereas that with two extra assessments (skip weeks 3 and 5 cohort (skip weeks 3 and 5 cohort v.
v. weekly co-weekly cohort) was 1.75 HRSD points. This suggests hort) was 1.75 HRSD points. This suggests that the therapeutic impact of follow-up that the therapeutic impact of follow-up assessments is cumulative and propor-assessments is cumulative and proportional. tional.
Control analysis Control analysis
To evaluate whether placebo effects are To evaluate whether placebo effects are otherwise comparable between the cohorts otherwise comparable between the cohorts of interest, we compared reductions in of interest, we compared reductions in HRSD scores from baseline to week 2 be-HRSD scores from baseline to week 2 between the weekly cohort and the skip week tween the weekly cohort and the skip week 5 and skip weeks 3 and 5 cohorts. Because 5 and skip weeks 3 and 5 cohorts. Because all three cohorts received weekly follow-up all three cohorts received weekly follow-up assessments through week 2, we predicted assessments through week 2, we predicted that reductions in HRSD scores would be that reductions in HRSD scores would be similar. The reduction in HRSD scores similar. The reduction in HRSD scores from baseline to week 2 in the weekly co-from baseline to week 2 in the weekly cohort was 5.35 points. In the two cohorts hort was 5.35 points. In the two cohorts that subsequently skipped one or two that subsequently skipped one or two follow-up assessments, the reduction in follow-up assessments, the reduction in HRSD scores was 5.41 points. Thus, HRSD scores was 5.41 points. Thus, placebo effects were comparable between placebo effects were comparable between the cohorts when the frequency of follow-the cohorts when the frequency of followup visits was the same. up visits was the same.
Participants receiving active Participants receiving active medication medication
We repeated all the analyses described We repeated all the analyses described above for participants receiving active above for participants receiving active medication. Reduction in HRSD score from medication. Reduction in HRSD score from week 4 to week 6 for the weekly cohort was week 4 to week 6 for the weekly cohort was 2.35 points compared with 1.38 for cohorts 2.35 points compared with 1.38 for cohorts who did not have a week 5 visit (a differ-who did not have a week 5 visit (a difference of 0.97 points). Reduction in HRSD ence of 0.97 points). Reduction in HRSD score from week 2 to week 4 for cohorts score from week 2 to week 4 for cohorts that met at week 3 (the weekly cohort and that met at week 3 (the weekly cohort and the skip week 5 cohort) was 3.69 points the skip week 5 cohort) was 3.69 points compared with 2.57 for cohorts that did compared with 2.57 for cohorts that did not have a week 3 visit (a difference of not have a week 3 visit (a difference of 1.12 points). Reductions in HRSD scores 1.12 points). Reductions in HRSD scores from week 2 to week 6 for the weekly co-from week 2 to week 6 for the weekly cohort, skip week 5 cohort and skip weeks 3 hort, skip week 5 cohort and skip weeks 3 and 5 cohort were 5.87, 5.05 and 4.29 re-and 5 cohort were 5.87, 5.05 and 4.29 respectively. One extra assessment visit there-spectively. One extra assessment visit therefore accounted for a reduction of 0.76 fore accounted for a reduction of 0.76 HRSD points whereas a second extra HRSD points whereas a second extra assessment accounted for an additional assessment accounted for an additional 0.82 points. For the control analysis, we 0.82 points. For the control analysis, we again compared reductions in HRSD scores again compared reductions in HRSD scores from baseline to week 2 in the weekly co-from baseline to week 2 in the weekly cohort with the two cohorts that skipped at hort with the two cohorts that skipped at least one follow-up assessment. Reductions least one follow-up assessment. Reductions in HRSD scores were 7.78 and 7.61 HRSD in HRSD scores were 7.78 and 7.61 HRSD points respectively, again suggesting com-points respectively, again suggesting comparable treatment effects except when there parable treatment effects except when there were differences in follow-up schedules. were differences in follow-up schedules.
DISCUSSION DISCUSSION
The ubiquitous and robust placebo res-The ubiquitous and robust placebo response has for years both intrigued and ponse has for years both intrigued and frustrated mood disorder researchers. frustrated mood disorder researchers. Although there is general consensus as to Although there is general consensus as to which factors are responsible for the which factors are responsible for the placebo response, it remains unclear how placebo response, it remains unclear how much each particular component contri-much each particular component contributes to the overall effect. One exception butes to the overall effect. One exception to this is the role that spontaneous improve-to this is the role that spontaneous improvement may play. In a meta-analysis com-ment may play. In a meta-analysis comparing treatment effect sizes for people paring treatment effect sizes for people with depression randomised to placebo with depression randomised to placebo with those randomised to no treatment, with those randomised to no treatment, spontaneous improvement was estimated spontaneous improvement was estimated to constitute about one-third of the placebo to constitute about one-third of the placebo response (Kirsch & Sapirstein, 1999 
Main results Main results
In the present study, we isolated one of the In the present study, we isolated one of the remaining components -the therapeutic remaining components -the therapeutic impact of follow-up assessments -to deter-impact of follow-up assessments -to determine the importance of this factor to the re-mine the importance of this factor to the remaining two-thirds of the placebo response. maining two-thirds of the placebo response.
We found that scheduling an extra follow-We found that scheduling an extra followup visit at week 3 was associated with an up visit at week 3 was associated with an additional 0.86-point reduction in HRSD additional 0.86-point reduction in HRSD scores, whereas scheduling an additional scores, whereas scheduling an additional week 5 visit was associated with an addi-week 5 visit was associated with an additional 0.67 reduction in HRSD scores. tional 0.67 reduction in HRSD scores. These reductions represent approximately These reductions represent approximately 40% of the placebo response that occurred 40% of the placebo response that occurred over their respective time frames. When we over their respective time frames. When we examined the cumulative effect of schedul-examined the cumulative effect of scheduling ing two two additional follow-up visits, we additional follow-up visits, we found that the therapeutic impact of each found that the therapeutic impact of each visit was cumulative and proportional. visit was cumulative and proportional. That is, one extra visit was associated with That is, one extra visit was associated with a 0.84 greater reduction in the HRSD score a 0.84 greater reduction in the HRSD score whereas a second extra visit was associated whereas a second extra visit was associated with a 0.91 further reduction in the HRSD with a 0.91 further reduction in the HRSD score. As further illustration of the impact score. As further illustration of the impact of follow-up assessments on the placebo of follow-up assessments on the placebo response, participants who were assessed response, participants who were assessed on a weekly basis experienced an overall on a weekly basis experienced an overall drop in HRSD scores of 9.6 points over drop in HRSD scores of 9.6 points over the course of 6 weeks. By comparison, the course of 6 weeks. By comparison, participants receiving placebo who were participants receiving placebo who were assessed only four times experienced only assessed only four times experienced only a 7.3-point drop in HRSD score. a 7.3-point drop in HRSD score.
Since follow-up assessments had a dis-Since follow-up assessments had a discernible therapeutic effect for participants cernible therapeutic effect for participants receiving placebo, we expected they would receiving placebo, we expected they would also have a discernible and comparable also have a discernible and comparable effect for those receiving active medication. effect for those receiving active medication. Indeed, each of our analyses from the Indeed, each of our analyses from the placebo cohorts was replicated for cohorts placebo cohorts was replicated for cohorts receiving active medication, as each addi-receiving active medication, as each additional follow-up visit was associated with tional follow-up visit was associated with a further reduction of 0.97-1.12 in HRSD a further reduction of 0.97-1.12 in HRSD scores. scores.
Design of meta-analysis Design of meta-analysis
The ideal method for evaluating the thera-The ideal method for evaluating the therapeutic impact of follow-up assessments on peutic impact of follow-up assessments on the placebo response would be to rando-the placebo response would be to randomise participants with depression receiving mise participants with depression receiving placebo to different follow-up schedules. placebo to different follow-up schedules. Such a study has not been performed to Such a study has not been performed to date and most likely never will. In the date and most likely never will. In the present meta-analysis, we have in effect present meta-analysis, we have in effect randomised cohorts rather than individ-randomised cohorts rather than individuals. Since the methodology of efficacy uals. Since the methodology of efficacy trials of antidepressants has remained trials of antidepressants has remained largely unchanged over the years (Thase, largely unchanged over the years (Thase, 1999) , heterogeneity between studies is 1999), heterogeneity between studies is likely to be minimal: all studies involved likely to be minimal: all studies involved out-patients with moderate-to-severe de-out-patients with moderate-to-severe depression who received identical treatment pression who received identical treatment (placebo) over the course of 6 weeks using (placebo) over the course of 6 weeks using the same outcome measure (the HRSD). the same outcome measure (the HRSD). Where an extra follow-up assessment was Where an extra follow-up assessment was conducted, a clear therapeutic effect was conducted, a clear therapeutic effect was associated with that visit as hypothesised. associated with that visit as hypothesised. Although it is possible that this could be at-Although it is possible that this could be attributable to random differences between tributable to random differences between studies, we would argue that this is extre-studies, we would argue that this is extremely unlikely. The present meta-analysis mely unlikely. The present meta-analysis included the majority of acute-phase, included the majority of acute-phase, placebo-controlled antidepressant trials placebo-controlled antidepressant trials published over the past two decades, and published over the past two decades, and our analyses were therefore based on large our analyses were therefore based on large sample sizes. Second, improvement on sample sizes. Second, improvement on placebo was comparable between all three placebo was comparable between all three cohorts during the first 2 weeks of treat-cohorts during the first 2 weeks of treatment when follow-up assessment ment when follow-up assessment schedules were identical. As this is the most schedules were identical. As this is the most direct method for evaluating random differ-direct method for evaluating random differences in placebo response rates, it would be ences in placebo response rates, it would be superfluous to attempt to control for other superfluous to attempt to control for other potential confounding variables such as potential confounding variables such as year of publication, episode duration, year of publication, episode duration, comorbidity, etc. Furthermore, all of our comorbidity, etc. Furthermore, all of our findings that supported a clear, therapeutic findings that supported a clear, therapeutic effect from assessment contact were effect from assessment contact were replicated in cohorts receiving active replicated in cohorts receiving active medication. medication.
We would argue that our results are not We would argue that our results are not undermined by relying solely on published undermined by relying solely on published studies. Publication bias is a concern for studies. Publication bias is a concern for many meta-analyses because negative trials many meta-analyses because negative trials often go unpublished, and attempts to often go unpublished, and attempts to establish effect sizes may consequently establish effect sizes may consequently overestimate treatment benefits. The goal overestimate treatment benefits. The goal of the present study, however, was to esti-of the present study, however, was to estimate the therapeutic impact of follow-up mate the therapeutic impact of follow-up assessments. The lack of inclusion of un-assessments. The lack of inclusion of unpublished studies would only undermine published studies would only undermine our results if unpublished studies were our results if unpublished studies were found to systematically have less therapeu-found to systematically have less therapeutic impact of their assessment visits (for ex-tic impact of their assessment visits (for example, if raters in unpublished studies were ample, if raters in unpublished studies were consistently less empathic). Unpublished consistently less empathic). Unpublished studies, however, by virtue of having failed studies, however, by virtue of having failed to separate drug from placebo, would be to separate drug from placebo, would be expected to have more rather than less expected to have more rather than less robust placebo response rates, and the ther-robust placebo response rates, and the therapeutic impact of follow-up assessments apeutic impact of follow-up assessments might, if anything, be more pronounced. might, if anything, be more pronounced.
Limitations Limitations
One limitation of our study is that because One limitation of our study is that because few studies published weekly or end-point few studies published weekly or end-point standard deviations of HRSD scores, we standard deviations of HRSD scores, we were unable to confirm that differences were unable to confirm that differences between cohorts were statistically signifi-between cohorts were statistically significant. Although our analyses yielded what cant. Although our analyses yielded what appears to be a large and consistent effect appears to be a large and consistent effect from extra follow-up visits, the lack of sta-from extra follow-up visits, the lack of statistical confirmation warrants caution in in-tistical confirmation warrants caution in interpreting these findings. We also wondered terpreting these findings. We also wondered whether the greater therapeutic effect found whether the greater therapeutic effect found in cohorts that met more frequently might in cohorts that met more frequently might be a consequence of greater retention rates be a consequence of greater retention rates in these cohorts. In most clinical trials, in these cohorts. In most clinical trials, rating scores for participants who drop rating scores for participants who drop out are handled using the last-observation-out are handled using the last-observationcarried-forward method of analysis. Per-carried-forward method of analysis. Perhaps participants who do not present on a haps participants who do not present on a weekly basis are more likely to drop out weekly basis are more likely to drop out and therefore not have the opportunity to and therefore not have the opportunity to demonstrate improvement. To address this demonstrate improvement. To address this concern, we evaluated completion rates in concern, we evaluated completion rates in each of the three cohorts and found no each of the three cohorts and found no correlation between frequency of visits correlation between frequency of visits and completion rates: skip week 3 and 5, and completion rates: skip week 3 and 5, 58.5% (326 of 557); skip week 5, 62.5% 58.5% (326 of 557); skip week 5, 62.5% (847 of 1356); weekly, 58.8% (403 of (847 of 1356); weekly, 58.8% (403 of 685). Thus, the therapeutic effect we found 685). Thus, the therapeutic effect we found does not appear to be a function of does not appear to be a function of improved adherence. improved adherence.
Design of trials Design of trials
Considering the relatively modest effect size Considering the relatively modest effect size of FDA-approved antidepressants over of FDA-approved antidepressants over placebo, that side-effects may unmask placebo, that side-effects may unmask raters in favour of eliciting drug-placebo raters in favour of eliciting drug-placebo differences (Greenberg differences (Greenberg et al et al, 1992) and that , 1992) and that most negative trials never get published, most negative trials never get published, several investigators have suggested that several investigators have suggested that the benefits of antidepressant medications the benefits of antidepressant medications have been exaggerated over the years have been exaggerated over the years (Fisher & Greenberg, 1997; Kirsch & (Fisher & Greenberg, 1997; Kirsch & Sapirstein, 1999) . Although these argu- Sapirstein, 1999) . Although these arguments are persuasive, we believe an alterna-ments are persuasive, we believe an alternative explanation also exists -that the tive explanation also exists -that the methodology used to elicit and establish methodology used to elicit and establish antidepressant efficacy is inefficient. As re-antidepressant efficacy is inefficient. As reviewed elsewhere (Posternak viewed elsewhere (Posternak et al et al, 2002 (Posternak et al et al, , 2002b , ), the methodology used in antidepressant the methodology used in antidepressant trials evolved largely from traditions estab-trials evolved largely from traditions established over three decades ago and has never lished over three decades ago and has never undergone empirical testing. Our results undergone empirical testing. Our results suggest that the frequent and extensive suggest that the frequent and extensive monitoring that occurs in clinical trials con-monitoring that occurs in clinical trials confers a significant therapeutic effect for fers a significant therapeutic effect for participants receiving placebo (and active participants receiving placebo (and active medication). High placebo response rates medication). High placebo response rates reduce treatment effect sizes and increase reduce treatment effect sizes and increase the risk that an efficacious agent will be the risk that an efficacious agent will be deemed ineffective. Although a comparable deemed ineffective. Although a comparable therapeutic effect from follow-up visits was therapeutic effect from follow-up visits was found in participants randomised to active found in participants randomised to active medication, reducing an equivalent amount medication, reducing an equivalent amount of 'noise' in both cohorts would have the of 'noise' in both cohorts would have the effect of increasing the power to detect dif-effect of increasing the power to detect differences between the active medication and ferences between the active medication and control group (Cohen, 1988) . control group (Cohen, 1988) .
Knowing the impact that follow-up as-Knowing the impact that follow-up assessments have on placebo response rates, sessments have on placebo response rates, the design of antidepressant trials could be the design of antidepressant trials could be modified either by reducing the amount of modified either by reducing the amount of time devoted to assessing participants in time devoted to assessing participants in follow-up, reducing the frequency of follow-up, reducing the frequency of follow-up assessments, or relying more on follow-up assessments, or relying more on off-site raters or interactive computer off-site raters or interactive computer assessment. Of course, consideration of assessment. Of course, consideration of these changes must be balanced against these changes must be balanced against ethical concerns of having insufficient mon-ethical concerns of having insufficient monitoring over the course of a clinical trial. itoring over the course of a clinical trial. This would apply both to participants ran-This would apply both to participants randomised to placebo and to those receiving a domised to placebo and to those receiving a putative antidepressant agent, especially if putative antidepressant agent, especially if there are concerns regarding the potential there are concerns regarding the potential for increased suicidal ideation following for increased suicidal ideation following the initiation of an antidepressant. the initiation of an antidepressant.
Explaining the placebo response Explaining the placebo response
Our results suggest that the follow-up Our results suggest that the follow-up assessment schedules of standard antide-assessment schedules of standard antidepressant efficacy trials convey a significant pressant efficacy trials convey a significant therapeutic effect for participants receiving therapeutic effect for participants receiving placebo, and that these assessment visits placebo, and that these assessment visits account for an estimated 40% of the account for an estimated 40% of the placebo response. This does not take into placebo response. This does not take into account the therapeutic effect of the initial account the therapeutic effect of the initial evaluation, which is typically much more evaluation, which is typically much more extensive than follow-up assessments and extensive than follow-up assessments and would be expected to convey a larger ther-would be expected to convey a larger therapeutic effect. For years, there has been apeutic effect. For years, there has been much speculation as to which ingredients much speculation as to which ingredients comprise the powerful and seemingly comprise the powerful and seemingly magical placebo pill, with some investiga-magical placebo pill, with some investigators even suggesting that different coloured tors even suggesting that different coloured pills may be associated with different pills may be associated with different placebo response rates (Jacobs & Nordan, placebo response rates (Jacobs & Nordan, 1979; Buckalew & Coffield, 1982 ). Our 1979 Buckalew & Coffield, 1982) . Our findings suggest that, after accounting for findings suggest that, after accounting for spontaneous improvement, the placebo spontaneous improvement, the placebo response in trials of antidepressants stems response in trials of antidepressants stems largely from the attention and care received largely from the attention and care received during the course of the clinical trial. during the course of the clinical trial. (1986) A double-blind comparative trial of zimelidine, A double-blind comparative trial of zimelidine, amitriptyline, and placebo in patients with mixed anxiety amitriptyline, and placebo in patients with mixed anxiety and depression. and depression. Pharmacopsychiatry Pharmacopsychiatry, , 19 19, 115^119. , 115^119.
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